Hepatobiliary disorders and complications of inflammatory bowel disease

Journal of Digestive Diseases

Volumn 12, Issue 4, 2011, Pages 245-256

  Venkatesh, Preethi G K ^a   Navaneethan, Udayakumar ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Drug induced hepatitis; Liver transplantation; Primary sclerosing cholangitis; Restorative proctocolectomy; Ulcerative colitis

Indexed keywords

IMMUNOGLOBULIN G4;

AMYLOIDOSIS; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; CANCER SURGERY; CHOLANGITIS; CHOLELITHIASIS; CROHN DISEASE; ENTERITIS; FATTY LIVER; GALLSTONE; GRANULOMATOUS HEPATITIS; HEPATOBILIARY DISEASE; HUMAN; LIVER ABSCESS; LIVER TOXICITY; LIVER TRANSPLANTATION; MEDICAL HISTORY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PORTAL VEIN THROMBOSIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; REVIEW; SURGEON; ULCERATIVE COLITIS;

BILIARY TRACT DISEASES; CHOLANGITIS, SCLEROSING; COMORBIDITY; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LIVER TRANSPLANTATION; PROCTOCOLECTOMY, RESTORATIVE;

EID: 79960737172     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00511.x     Document Type: Review

References (147)

1. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001; 96: 1116-22.
2. Ricart E, Panaccione R, Loftus EV etal. Autoimmune disorders and extraintestinal manifestations in first-degree familial and sporadic inflammatory bowel disease: a case-control study. Inflamm Bowel Dis 2004; 10: 207-14.
3. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129: 827-36.
4. Mendoza JL, Lana R, Taxonera C, Alba C, Izquierdo S, Diaz-Rubio M. Extraintestinal manifestations in inflammatory bowel disease: differences between Crohn's disease and ulcerative colitis. Med Clin (Barc) 2005; 125: 297-300.
5. Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 1598-619.
6. Olsson R, Danielsson A, Jarnerot G etal. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-23.
7. Smith M, Loe S. Sclerosing cholangitis: review of recent case reports and associated diseases and four new cases. Am J Surg 1965; 110: 239-46.
8. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-40.
9. Loftus EV, Sandborn WJ, Lindor KD etal. Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997; 3: 288-302.
10. Faubion WA, Loftus EV, Sandborn WJ etal. Pediatric 'PSC-IBD': a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr 2001; 33: 296-300.
11. Loftus EV, Harewood GC, Loftus CG etal. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
12. Heuschen U, Hinz U, Allemeyer E etal. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001; 120: 841-7.
13. Joo M, Abreu-e-Lima P, Farraye F etal. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009; 33: 854-62.
14. Lundqvist K, Broome U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 1997; 40: 451-6.
15. Penna C, Dozois R, Tremaine W etal. Pouchitis after ileal pouch anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-9.
16. Broome U, Lofberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis Colon Rectum 1995; 38: 1301-5.
17. Soetikno R, Lin O, Heidenreich P. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54.
18. Chapman RW, Marborgh BA, Rhodes JM etal. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980; 21: 870-7.
19. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332: 924-33.
20. Helzberg JH, Peterson JM, Boyer JL. Improved survival with primary sclerosing cholangitis: a review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987; 92: 1869-75.
21. Schrumpf E, Elgjo K, Fausa O etal. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15: 689-97.
22. Shepherd HA, Selby WS, Chapman RW etal. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 52: 503-13.
23. Rasmussen HH, Fallingborg JF, Mortensen PB etal. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32: 604-10.
24. Shen B, Bennett AE, Navaneethan U etal. Primary sclerosing cholangitis is associated with endoscopic and histologic inflammation of the distal afferent limb in patients with ileal pouch-anal anastomosis. Inflamm Bowel Dis 2010; doi: 10.1002/ibd.21594 [Epub ahead of print].
25. Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan - analysis of 192 cases. J Gastroenterol 1997; 32: 134-7.
26. Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 2002; 8: 356-61.
27. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36: 908-12.
28. Higashi H, Yanaga K, Marsh JW etal. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology 1990; 11: 477-80.
29. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997; 92: 204-11.
30. Rutter MD, Saunders BP, Wilkinson KH etal. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-6.
31. Stahlberg D, Veress B, Tribukait B, Broome U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 2003; 46: 770-8.
32. Ludwig J, Barham SS, La Russo NF etal. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1981; 1: 632-40.
33. MacCarty RL, La Russo NF, May GR etal. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances. Radiology 1985; 156: 43-6.
34. Broome U, Olsson R, Loof L etal. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-15.
35. Rabinovitz M, Gavaler JS, Schade RR etal. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. Hepatology 1990; 11: 7-11.
36. Farrant JM, Doherty DG, Donaldson PT etal. Amino acid substitutions at positions 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology 1992; 16: 390-5.
37. Olerup O, Olsson R, Hultcrantz R etal. HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis. Gastroenterology 1995; 108: 870-8.
38. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 3195-9.
39. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993; 17: 411-7.
40. Bansi DS, Fleming KA, Chapman RW. Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 1996; 38: 384-9.
41. Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol 2005; 28: 115-33.
42. Terjung B, Spengler U, Sauerbruch T, Worman HJ. 'Atypical p-ANCA' in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119: 310-22.
43. Mandal A, Dasgupta A, Jeffers L etal. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Gastroenterology 1994; 106: 185-92.
44. O'Mahony CA, Vierling JM. Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 2006; 26: 3-21.
45. Worthington J, Cullen S, Chapman R. Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005; 28: 93-103.
46. Fausa O, Schrumpf E, Elgio K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9.
47. Aoki CA, Bowlus CL, Gershwin ME. The immunobiology of primary sclerosing cholangitis. Autoimmun Rev 2005; 4: 137-43.
48. Kono K, Ohnishi K, Omata K etal. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988; 94: 787-96.
49. Bjornsson ES, Kilander AF, Olsson RG. Bile duct bacterial isolates in primary sclerosing cholangitis and certain other forms of cholestasis - a study of bile cultures from ERCP. Hepatogastroenterology 2000; 47: 1504-8.
50. Terjung B, Muennich M, Gottwein J, Soehne J etal. Identification of myeloid-specific tubulin-beta isotype 5 as target antigen of antineutrophil cytoplasmic antibodies in autoimmune liver disorders. Hepatology 2005; 42 (Suppl 1): 288A.
51. Erickson HP. FtsZ, a prokaryotic homolog of tubulin? Cell 1995; 80: 367-70.
52. Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a 'leaky gut'? Clin Rev Allergy Immunol 2009; 36: 40-51.
53. Porayko MK, Wiesner RH, LaRusso NF etal. Patients with asymptomatic primary sclerosing cholangitis frequently have progressive disease. Gastroenterology 1990; 98: 1594-602.
54. Farrant JM, Hayllar KM, Wilkinson ML etal. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100: 1710-7.
55. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W etal. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51: 562-6.
56. Ludwig J, LaRusso NF, Wiesner RH. Primary sclerosing cholangitis. In: Peters RL, Craig JG, eds. Contemporary Issues in Surgical Pathology: Liver Pathology. New York: Churchill Livingstone, 1986; 193-213.
57. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004; 39: 204-10.
58. Kim WR, Therneau TM, Wiesner RH etal. A revised natural history model for primary sclerosing cholangitis obviates the need for liver histology. Mayo Clin Proc 2000; 75: 688-94.
59. Bergquist A, Ekbom A, Olsson R etal. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-7.
60. Fevery J, Verslype C, Lai G, Aerts R, Van Steenbergen W. Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci 2007; 52: 3123-35.
61. Boberg KM, Jebsen P, Clausen OP etal. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45: 568-74.
62. Rudolph G, Gotthardt D, Kloeters-Plachky P, Rost D, Kulaksiz H, Stiehl A. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 2010; 53: 313-7.
63. Mir-Madjlessi SH, Farmer RG, Sivak JMV. Bile duct carcinoma in patients with ulcerative colitis relationship to sclerosing cholangitis: report of six cases and review of the literature. Dig Dis Sci 1987; 32: 145-54.
64. Wee A, Ludwig J, Coffey JRJ, LaRusso NF, Wiesner RH. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol 1985; 16: 719-26.
65. Erichsen R, Jepsen P, Vilstrup H, Ekbom A, Sørensen HT. Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003. Eur J Epidemiol 2009; 24: 513-20.
66. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91: 854-62.
67. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 311-6.
68. Chalasani N, Baluyut A, Ismail A etal. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31: 7-11.
69. Claessen MM, Vleggaar FP, Tytgat KM, Siersema PD, van Buuren HR. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50: 158-64.
70. Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol 2010; 34: 27-34.
71. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-5.
72. Olsson R, Boberg KM, de Muckadell OS etal. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129: 1464-72.
73. Cullen SN, Rust C, Fleming K etal. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48: 792-800.
74. Lindor KD, Kowdley KV, Luketic VA etal. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50: 808-14.
75. Tung BY, Emond MJ, Haggitt RC etal. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95.
76. Baluyut AR, Sherman S, Lehman GA etal. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 2001; 53: 308-12.
77. Tischendorf JJ, Meier PN, Strassburg CP etal. Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 2006; 41: 1227-34.
78. Graziadei IW, Wiesner RH, Marotta PJ etal. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-7.
79. Graziadei IW, Wiesner RH, Batts KP etal. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999; 29: 1050-6.
80. Wee A, Ludwig J, Coffey RJ Jr etal. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol 1985; 16: 719-26.
81. Angulo P, Maor-Kendler Y, Lindor KD. Small-duct primary sclerosing cholangitis: prevalence and natural history. Hepatology 2002; 35: 1494-500.
82. Björnsson E, Boberg KM, Cullen S etal. Patients with small duct primary sclerosing cholangitis have a favorable long-term prognosis. Gut 2002; 51: 731-5.
83. Broomé U, Glaumann H, Lindstöm E etal. Natural history and outcome in 32 Swedish patients with small duct primary sclerosing cholangitis (PSC). J Hepatol 2002; 36: 586-9.
84. Björnsson E, Olsson R, Bergquist A etal. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008; 134: 975-80.
85. Saldeen K, Friman S, Olausson M, Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999; 34: 535-40.
86. Befeler AS, Lissoos TW, Schiano TD etal. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393-6.
87. Riley TR, Schoen RE, Lee RG, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease. Am J Gastroenterol 1997; 92: 279-82.
88. Papatheodoridis GV, Hamilton M, Mistry PK etal. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 595-6.
89. Verdonk RC, Dijkstra G, Haagsma EB etal. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-9.
90. Zins BJ, Sandborn WJ, Penna CR etal. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol 1995; 90: 2177-80.
91. Freeman K, Shao Z, Remzi FH etal. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol 2008; 6: 62-8.
92. Mathis KL, Dozois EJ, Larson DW etal. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br J Surg 2008; 95: 882-6.
93. Poritz LS, Koltun WA. Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis. Dis Colon Rectum 2003; 46: 173-8.
94. Cangemi JR, Wiesner RH, Beaver SJ etal. Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 1989; 96: 790-4.
95. Mikkola K, Kiviluoto T, Riihelä M, Taavitsainen M, Järvinen HJ. Liver involvement and its course in patients operated on for ulcerative colitis. Hepatogastroenterology 1995; 42: 68-72.
96. Lepistö A, Kivistö S, Kivisaari L, Arola J, Järvinen HJ. Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolectomy for ulcerative colitis. Int J Colorectal Dis 2009; 24: 1169-74.
97. Obusez EC, Lian L, Shao Z, O'Shea R, Kiran RP, Shen B. Impact of ulcerative colitis and ileal-pouch anal anastomosis on the outcome of orthotopic liver transplantation for primary sclerosing cholangitis. Gastroenterology 2010; 138: S-211.
98. Hampton DD, Poleski MH, Onken JE. Inflammatory bowel disease following solid organ transplantation. Clin Immunol 2008; 128: 287-93.
99. Navaneethan U, Venkatesh PG, Wang J. CMV ileitis in a patient following orthotopic liver transplantation-differentiating from de novo IBD. J Crohns Colitis 2011; 5: 354-9.
100. Wörns MA, Lohse AW, Neurath MF etal. Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation. Am J Gastroenterol 2006; 101: 1931-7.
101. Barritt AS, Zacks SL, Rubinas TC, Herfarth HH. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature. Inflamm Bowel Dis 2008; 14: 1695-700.
102. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology 2001; 33: 994-1002.
103. Gregorio GV, Portmann B, Karani J etal. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001; 33: 544-53.
104. Floreani A, Rizzotto ER, Ferrara F etal. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005; 100: 1516-22.
105. Perdigoto R, Carpenter H, Czaja A. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14: 325-31.
106. Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology 2001; 34: 659-65.
107. de Suray N, Van Beers B, Sempoux C etal. Autoimmune pancreatitis, sclerosing cholangitis, liver inflammatory pseudotumors, retroperitoneal fibrosis, lymphadenopathy, and sialoadenitis in a single patient: a multifaced expression of a hitherto unrecognized systemic autoimmune syndrome? Pancreas 2009; 38: 476-8.
108. Bjornsson E, Chari ST, Smyrk TC, Lindor K. Immunoglobulin G4 associated cholangitis: description of an emerging clinical entity based on review of the literature. Hepatology 2007;45: 1547-54.
109. Mendes FD, Jorgensen R, Keach J etal. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. Am J Gastroenterol 2006; 101: 2070-5.
110. Zhang LL, Lewis JT, Abraham SC etal. IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol 2010; 34: 88-94.
111. Dastis SN, Latinne D, Sempoux C, Geubel AP. Ulcerative colitis associated with IgG4 cholangitis: similar features in two HLA identical siblings. J Hepatol 2009; 51: 601-5.
112. Webster GJ, Pereira SP, Chapman RW. Autoimmune pancreatitis/IgG4-associated cholangitis and primary sclerosing cholangitis - overlapping or separate diseases? J Hepatol 2009; 51: 398-402.
113. Hill GL, Mair WS, Goligher JC. Gallstones after ileostomy and ileal resection. Gut 1975; 16: 932-6.
114. Whorwell PJ, Hawkins R, Dewbury K, Wright R. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn's disease. Dig Dis Sci 1984; 29: 930-3.
115. Lorusso D, Leo S, Mossa A, Misciagna G, Guerra V. Cholelithiasis in inflammatory bowel disease: a case-control study. Dis Colon Rectum 1990; 33: 791-4.
116. Lapidus A, Bangstad M, Astrom M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn's disease. Am J Gastroenterol 1999; 94: 1261-6.
117. Fraquelli M, Losco A, Visentin S etal. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med 2001; 161: 2201-4.
118. Bargiggia S, Maconi G, Elli M etal. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single centre. J Clin Gastroenterol 2003; 36: 417-20.
119. Dowling RH, Bell GD, White J. Lithogenic bile in patients with ileal dysfunction. Gut 1972; 13: 415-20.
120. Lapidus A, Einarsson K. Effects of ileal resection on biliary lipids and bile acid composition in patients with Crohn's disease. Gut 1991; 32: 1488-91.
121. Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn's disease. Inflamm Bowel Dis 1998; 4: 89-94.
122. Brink MA, Slors JFM, Keulemans YCA etal. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology 1999; 116: 1420-7.
123. Parente F, Pastore L, Bargiggia S etal. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45: 1267-74.
124. Damiao AO, Sipahl AM, Vezozzo DP etal. Gallbladder hypokinesis in Crohn's disease. Digestion 1997; 58: 458-63.
125. Annese V, Vantrappen G. Gallstones in Crohn's disease: another hypothesis. Gut 1994; 35: 1676.
126. Pitt HA, King W, Mann L etal. Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am J Surg 1983; 145: 106-12.
127. Jackson LM, O'Gorman PJ, O'Connell J, Cronin CC, Cotter KP, Shanahan F. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 1997; 90: 183-8.
128. Sridhar AR, Parasa S, Navaneethan U, Crowell MD, Olden K. Comprehensive study of cardiovascular morbidity in hospitalized inflammatory bowel disease patients. J Crohns Colitis 2011; 5: 287-94.
129. Miehsler W, Reinisch W, Valic E etal. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 2004; 53: 542-8.
130. Liappis AP, Roberts AD, Schwartz AM etal. Thrombosis and infection: a case of transient anti-cardiolipin antibody associated with pylephlebitis. Am J Med Sci 2003; 325: 365-8.
131. Sanghavi P, Paramesh A, Dwivedi A etal. Mesenteric arterial thrombosis as a complication of Crohn's disease. Dig Dis Sci 2001; 46: 2344-46.
132. Vakil N, Hayne G, Sharma A etal. Liver abscess in Crohn's disease. Am J Gastroenterol 1994; 89: 1090-5.
133. Margalit M, Elinav H, Ilan Y, Shalit M. Liver abscess in inflammatory bowel disease: Report of two cases and review of the literature. J Gastroenterol Hepatol 2004; 19: 1338-42.
134. Hazzan D, Fishman E, Heller E etal. Liver abscess in Crohn's disease: a report of three cases. Mt Sinai J Med 2004; 71: 351-55.
135. Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995; 21: 1114-20.
136. Baker ME, Remzi F, Einstein D etal. CT depiction of portal vein thrombi after creation of ileal pouch-anal anastomosis. Radiology 2003; 227: 73-9.
137. Remzi FH, Fazio VW, Oncel M etal. Portal vein thrombi after restorative proctocolectomy. Surgery 2002; 132: 655-61.
138. Ball CG, MacLean AR, Buie WD, Smith DF, Raber EL. Portal vein thrombi after ileal pouch-anal anastomosis: its incidence and association with pouchitis. Surg Today 2007; 37: 552-7.
139. Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol 2003; 9: 878-80.
140. Koulentaki M, Koutroubakis IE, Petinaki E etal. Ulcerative colitis associated with primary biliary cirrhosis. Dig Dis Sci 1999; 44: 1953-6.
141. Lever E, Balasubramanian K, Condon S etal. Primary biliary cirrhosis associated with ulcerative colitis. Am J Gastroenterol 1993; 88: 945-7.
142. Riegler G, D'Inca R, Sturniolo GC etal. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Scand J Gastroenterol 1998; 33: 93-8.
143. de Dombal FT, Goldie W, Watts J McK, Goligher JC. Hepatic histological changes in ulcerative colitis. Scand J Gastroenterol 1966; 1: 220-7.
144. Navaneethan U, Remzi FH, Nutter B, Fazio VW, Shen B. Risk factors for abnormal liver function tests in patients with ileal pouch-anal anastomosis for underlying inflammatory bowel disease. Am J Gastroenterol 2009; 104: 2467-75.
145. Greenstein AJ, Sachar DB, Panday AK etal. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71: 261-70.
146. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001; 7: 295-300.
147. Callen JP, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978; 71: 1159-60.